中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

42 records (took 0.056 seconds)

    Combinations
    2.
    发明授权
    Combinations 有权

    公开(公告)号：US10716787B2

    公开(公告)日：2020-07-21

    申请号：US15955149

    申请日：2018-04-17

    Applicant: ASTEX THERAPEUTICS LTD

    Inventor： Eleonora Jovcheva ,  Timothy Pietro Suren Perera

    IPC: A61K31/4985 ,  A61K31/5025 ,  A61K31/498 ,  A61K45/06

    Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor.The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.The FGFR inhibitor (N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially.The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

    COMBINATIONS
    5.
    发明申请
    COMBINATIONS 有权

    公开(公告)号：US20210038598A1

    公开(公告)日：2021-02-11

    申请号：US16931728

    申请日：2020-07-17

    Applicant: ASTEX THERAPEUTICS LTD

    Inventor： Eleonora JOVCHEVA ,  Timothy Pietro Suren PERERA

    IPC: A61K31/4985 ,  A61K31/498 ,  A61K31/5025 ,  A61K45/06

    Abstract: The invention relates to a combination of a first compound selected from N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5 -dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3 -(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof; and a second compound which is a cMet inhibitor.
    The combination is for use in the treatment of a proliferative disorder, in particular for use in the treatment of cancer.
    The FGFR inhibitor (N-(3,5 -dimethoxyphenyl)-N-(1-methylethyl)-N-[3 -(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine or a pharmaceutically acceptable salt thereof or a solvate thereof, and N-(2-fluoro-3,5-dimethoxyphenyl)-N-(1H-imidazol-2-ylmethyl)-3-(1-methyl-1H-pyrazol-4-yl)pyrido[2,3-b]pyrazin-6-amine or a pharmaceutically acceptable salt thereof or a solvate thereof) and the cMet inhibitor can be administered simultaneously, separately or sequentially.
    The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.

Patent Agency Ranking